You are here

Recent Pfizer Press Releases

4/21/16 2:00pm EDT
Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 28, 2016.

more...
4/19/16 8:00am EDT
Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)

Phase 3 Trial Provides Confirmatory Evidence for IBRANCE in the First-Line Setting and Will Support Global Regulatory Submissions

4/7/16 8:30am EDT
Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care

Experimental “Internet of Things” System Uses Connected Devices to Enable Remote Measurement of Health and Quality of Life in Real-Time

Multi-Year Project Could Potentially Change How Clinical Trials are Conducted

NEW YORK & ARMONK, N.Y.--Pfizer Inc. (NYSE:PFE) and IBM (NYSE:IBM) today announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

more...
4/6/16 11:00am EDT
Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®

Four-Dose Vial Will Help Address Infrastructure Challenges in Developing Countries

NEW YORK--Pfizer Inc. (NYSE:PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing.

more...
4/6/16 6:45am EST
Pfizer Announces Termination of Proposed Combination with Allergan

NEW YORK, N.Y., April 6 - Pfizer Inc. (NYSE: PFE) today announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.

more...
4/5/16 5:34pm EDT
FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

NEW YORK--The United States (U.S.) Food and Drug Administration (FDA) today approved Celltrion’s INFLECTRA™ (biosimilar infliximab) across all eligible indications of the reference product, Remicade® (infliximab).1INFLECTRA is now the first and only biosimilar monoclonal antibody (mAb) therapy, and only the second biosimilar, to be approved in the U.S.

more...
4/5/16 8:00am EDT
Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinom

  • JAVELIN Renal 101 marks first Phase III study to evaluate avelumab in combination with a small molecule tyrosine kinase inhibitor therapy
  • Combination approach leverages Pfizer’s broad oncology portfolio and heritage in renal cell carcinoma
  • First-line study evaluating avelumab in combination with INLYTA® (axitinib) compared with SUTENT® (sunitinib malate) monotherapy

DARMSTADT, Germany & NEW YORK--Merck and Pfizer (NYSE:PFE) today announced the treatment of the first patient in a Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal ant

more...
4/5/16 7:00am EST
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

NEW YORK, N.Y., April 5 – Pfizer Inc. announced today top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Psoriatic Arthritis triaL (OPAL) Broaden.

more...
4/4/16 7:05pm EDT
Pfizer and Allergan Issue Statement

NEW YORK--Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today issued the following statement regarding the recently issued Department of Treasury Notice:

“We are conducting a review of the U.S. Department of Treasury’s actions announced today. Prior to completing the review, we won’t speculate on any potential impact.”

more...
4/1/16 8:00am EDT
Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

SPIRE-AI study evaluating bococizumab administered with pre-filled pen (autoinjector) met co-primary endpoints

 

 

 

more...
3/31/16 4:29pm EDT
Pfizer Inc. (NYSE: PFE) today issued the following statement:

 

 

 

 

A false press release related to drug pricing and linking to a fake web site was anonymously issued earlier today. It was erroneously attributed to Pfizer and should be disregarded. Pfizer is investigating this matter and evaluating its legal options against the parties responsible. Pfizer is committed to engaging in an honest discussion and real dialogue about the issues that matter to patients.

more...
3/30/16 12:41pm EDT
Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination

  • The request was fully anticipated as part of the regulatory process
  • Pfizer and Allergan continue to expect the transaction to close in the second half of 2016

Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today announced that the companies have received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to their previously announced pending combination.

more...
3/30/16 7:45am EDT
3/22/16 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 3, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2016 Performance Report, to be issued that morning.

more...
3/22/16 8:30am EDT
Pfizer Joins The Human Vaccines Project To Help Decode The Immune System

By Pooling Knowledge and Resources From Academia, Government, and Industry Partners, the Consortium Will Evaluate Human Immune Responses with the Goal to Potentially Speed Vaccines and Immunotherapeutic Development

Pfizer Inc. (NYSE:PFE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer.

more...
3/18/16 11:00am EST
Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials

Detailed Results from OCTAVE Induction 1 and 2 Presented During Oral Session at 11th Congress of ECCO

Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program at the 11th Congress of ECCO.

more...
3/16/16 8:00am EST
Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO

Seven Abstracts, Including Pivotal Phase 3 Data in Ulcerative Colitis, Accepted for Presentation

Pfizer Inc. (NYSE:PFE) announced today that seven abstracts reporting on new research for tofacitinib in ulcerative colitis (UC) and Crohn’s disease will be presented at the 11th Congress of ECCO, which will be held March 16-19 in Amsterdam, The Netherlands. Among the abstracts are detailed results from two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program.

more...
3/11/16 1:10pm EST
XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer

XALKORI is the first and only FDA-approved biomarker-driven therapy for ROS1-positive metastatic NSCLC

Pfizer Inc. (NYSE:PFE) today announced that the U.S.

more...

Pages